Company Overview
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -86.57% |
| 6 Months: | +47.73% |
| 3 Months: | +9.70% |
| 1 Month: | +7.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)58.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LNAI Lunai Bioworks Inc. PHARMA | 2.60 | -0.04 | $11.79M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 925 | - | - | - | - | - | - | - | 42.52K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.94K |
| Gross Profit | -15.27K | - | -17.74K | -64.27K | -143.50K | -70.16K | -44.62K | - | 37.28K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.94K |
| Operating Income | -339.26K | - | -412.11K | -568.10K | -513.74K | -935.28K | -865.48K | -341.39K | -594.94K | -513.60K | -852.29K | -548.78K | -351.03K | -625.77K | -1.28M | -3.24M | -1.81M | -4.38M | -2.69M | -2.44M | -2.82M | -3.83M | -2.86M | -3.31M | -3.05M | -7.50M | -6.33M | -4.03M | -7.19M | -4.37M | -4.06M | -8.88M | -4.27M | -51.38M | -53.34M | -4.55M | -4.16M | -3.31M | -1.82M | -1.48M |
| Net Income | -371.55K | -8.64K | -426.05K | -469.45K | -535.24K | -953.13K | -1.25M | -350.30K | -421.78K | -207.56K | -793.18K | -918.60K | -246.17K | -225.78K | -1.08M | -2.96M | -350.08K | -16.11M | -2.73M | -4.08M | -1.72M | -1.51M | -2.40M | -2.93M | -4.03M | -10.41M | -6.58M | -6.20M | -7.70M | -4.46M | -4.33M | -9.18M | -4.53M | -58.99M | -44.21M | -7.25M | 189.18K | 2.82M | -1.80M | -2.57M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.14 | -0.08 | -0.08 | -0.14 | -0.07 | -0.54 | -2.76 | -0.45 | 0.00 | 0.13 | -0.08 | -0.10 |
| R&D Expense | 0 | - | - | - | 143.15K | - | 151.81K | 101.76K | 277.65K | 235.93K | 17.10K | 13.79K | 16.29K | 153.65K | 219.97K | 137.92K | 493.56K | 788.97K | 730.25K | 520.19K | 561.47K | 2.31M | 1.05M | 1.33M | 1.12M | 3.06M | 2.34M | 1.21M | 2.61M | 325.96K | 239.14K | 566.64K | 620.52K | 1.09M | 390.19K | 161.08K | - | 24.41K | 45.87K | 15.95K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2012 | Mar 2013 | Dec 2013 | Dec 2014 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | - | 32.77K | 0 | 42.77K | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | -76.53K | -295.66K | 37.49K | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | -1.74M | -2.43M | -2.12M | -2.40M | -5.33M | -10.99M | -11.92M | -23.40M | -116.08M | -38.56M | -81.64M | -188.97M |
| Net Income | -29.95K | -37.59K | -2.15M | -2.37M | -1.74M | -2.14M | -6.31M | -18.02M | -11.42M | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -2.16 | -0.71 | -0.91 | -1.08 |
| R&D Expense | - | - | - | - | 804.19K | 62.76K | 616.96K | 2.50M | 4.69M | 15.72M | 8.37M | 4.17M | 2.71M | 537.43K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2011 | Mar 2011 | Mar 2012 | Mar 2013 | Dec 2013 | Dec 2014 | Jun 2015 | Jul 2015 | Mar 2016 | Jun 2016 | Jul 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 0 | 13.55K | 19.96K | 450.47K | 5.24M | 2.07M | - | - | 870.83K | - | 4.52M | 182.50M | 179.88M | 178.10M | 189.61M | 84.63M | 58.30M | 163.13M | 8.23M |
| Total Equity | 0 | -8.73K | -13.68K | -51.27K | -1.68M | 3.48M | 1.08M | - | - | -637.40K | - | 1.53M | 158.74M | 173.10M | 166.27M | 174.66M | 72.62M | 46.50M | 131.98M | -21.35M |
| Cash & Equivalents | - | - | - | - | 18.79K | 3.01M | 421.14K | 421.14K | 151.22K | 23.37K | 23.37K | 3.94M | 15.60M | 12.28M | 8.70M | 20.66M | 9.17M | 1.87M | 220.47K | 92.70K |
| Long Term Debt | - | - | - | - | 728.00K | 99.95K | - | - | - | 102.88K | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | 2.13M | 1.76M | 995.74K | - | - | 1.51M | - | 2.99M | 23.76M | 6.78M | 11.83M | 14.94M | 12.01M | 11.80M | 31.15M | 29.58M |
| Current Liabilities | - | 8.73K | 27.23K | 71.23K | 2.13M | 1.76M | 995.74K | - | - | 1.51M | - | 2.99M | 873.72K | 1.11M | 1.33M | 1.89M | 6.45M | 11.02M | 30.31M | 29.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2012 | Mar 2013 | Dec 2013 | Dec 2014 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.95K | -30.09K | -2.13M | -2.03M | -1.47M | -1.18M | -4.34M | -8.51M | -10.46M | -20.61M | -15.73M | -11.77M | -10.97M | -7.87M |
| Investing Cash Flow | -13.22K | - | -105.02K | -1.95M | 1.05M | -196.14K | -575.73K | -716.67K | -184.46K | -48.89K | -5.16K | -29.77K | -1.26M | -500.00K |
| Financing Cash Flow | 38.50K | 36.50K | 2.47M | 6.67M | - | 5.51M | 16.71M | 6.02M | 7.20M | 32.60M | 4.25M | 4.52M | 10.52M | 8.38M |
| Capital Expenditure | - | - | - | - | - | - | -30.00K | -716.67K | -184.46K | -48.89K | -5.16K | -29.77K | -70.43K | - |
| Free Cash Flow | - | - | - | - | - | - | -4.37M | -9.22M | -10.64M | -20.66M | -15.74M | -11.80M | -11.04M | - |
Ratios (Annual)
Figures in %.
| Metric | Mar 2012 | Mar 2013 | Dec 2013 | Dec 2014 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | -233.6% | - | 87.7% | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -5,306.8% | - | -4,959.0% | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | -6,553.2% | - | -4,057.2% | - | - | - | - | - | - | - | - | - |
| ROE % | 218.9% | 73.3% | 127.5% | -68.1% | 272.2% | -139.8% | -4.0% | -10.4% | -6.9% | -15.3% | -156.2% | -85.3% | -67.0% | 833.8% |
| ROCE % | - | - | 103.3% | -69.8% | 332.7% | -156.6% | -2.9% | -6.1% | -6.7% | -12.5% | -148.5% | -81.6% | -61.5% | 903.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ground Swell Capital, LLC | 1.17% | 53.21K | $123.98K |
| 2 | Geode Capital Management, LLC | 0.53% | 24.16K | $56.28K |
| 3 | Jane Street Group, LLC | 0.52% | 23.68K | $55.18K |
| 4 | Blackrock Inc. | 0.35% | 15.91K | $37.06K |
| 5 | Vanguard Capital Management LLC | 0.35% | 16.08K | $37.47K |
| 6 | Virtu Financial LLC | 0.28% | 12.86K | $29.97K |
| 7 | Vanguard Fiduciary Trust Co | 0.19% | 8.64K | $20.14K |
| 8 | Royal Bank of Canada | 0.04% | 1.69K | $3.93K |
| 9 | Tower Research Capital LLC (TRC) | 0.03% | 1.41K | $3.27K |
| 10 | Group One Trading, LLC | 0.01% | 544 | $1.27K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LNAI
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNSG00WjY2U1NPcnZ2YU9vbEZpckpDS1dCTEF0NGlVNUhqYUdTeV9PeW95MDdKTmxOdWdfaEJueFNnY0NIVnJlN3ZXdC00QVNSYTlGSEx3N0E5RVJMSHpSdmdtcEV6eUY5MkR0VHRYenVneDZnYmlodGVYdkVqS3NYWFJjNmE3VUJZd2pSRV…
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNQXdfMkR0N3F6MHhuMDE4ZTE2ZDdGeERya0dPWVpSNUpOZGFQSkJTaGlQdENjNTVzS0N1QkQtY05XcVZKVTJJWTByNGFQRFMwLXY2U0FobGxZTGlOd3VRSWxZMS1rMTVmSi1jQzd4RVJNcER1Z25pRnoxSE81STdOMEFXNW9TOFowVHUtaH…
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNVVV4Rzg4ZUx5MGpUNk9tWTN5VVBRRW43elVweDkzN0tZS1pnbjlqRkJJVy1YalNDY2M5Z0ZsejdLdWc0VVRQVlEzWWh5Q2t1S1JBUHZLQXZabVhJcUt6T041UzhsUTVnQTZLNFNtUzZvM3pQQzhjcWJ4V3l0STIzcHAwbDVCaGdUU0lsRH…
Why Did LNAI Stock Soar Over 100% In Pre-Market Trading Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxORVp5a2VFeEx4Ni1leFFLV3prRnFpc0dFN2xSU1J5YXE3YkRxZkZEbkp6bjFkdWVNQmNoMmpOU1dRWE5kNFlUeW9YYWNQd01FSEdUcDhsSFVOTTVzQ0JWUWlobXZLU0l3RjFxSm04WVpPM1Qtb1QzdGc0NmZsNmJJV0hOWllNMU1GYm9Yam…
Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOSlJralpRVHZRNHZJTXJfVGlocjBLOUxmSWRVRThFSmxZZ1U0U2FPZ1p6ZFFOeEZrLVVYU0hpNmY5bW5DN1lDdGlXX29iS0xzQU9OcE5tLWNBNlJ3NXRMOTUzMXF2OHVGblBpR0VFTUY4U2xwa1lRbjlYX0xqZXVqRnBXb1ZwdVlwcGE4MX…
LNAI - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE0wMFVtanVYNEIyTFVtTENtak1LVWFOMnQ2VGR2REVDcnNSNm9OOTk3NWx2RjdwcFRxYndPaWlMdmNscmZxVFE?oc=5" target="_blank">LNAI</a> <font color="#6f6f6f">Finviz</font>…
LNAI — Frequently Asked Questions
What is the current share price of Lunai Bioworks Inc. (LNAI)?
As of 2026-09-19 21:16 PDT, Lunai Bioworks Inc. (LNAI) trades at $2.60 on NasdaqCM. Its 52-week range is $1.47 to $20.64.
What is the market capitalisation of LNAI?
Lunai Bioworks Inc. (LNAI) has a market capitalisation of $11.79M on NasdaqCM.
What is the P/E ratio of LNAI?
LNAI trades at a trailing price-to-earnings (P/E) ratio of -0.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.09.
Is LNAI a good stock to buy?
This page provides a data-driven analysis of Lunai Bioworks Inc. (LNAI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.